TORn in Two Over Breast Cancer Drug Resistance
Knowing the genetic makeup of patient tumors permits the development of new DNA-based diagnostics, such as BEAMing and PARE. By incorporating these new tools into future trials, we should be able to concurrently learn about drug resistance and significantly improve patient responses.
ConclusionEthyl acetate &Water extracts have represented potent activity against Salmonella typhi, Escherichia coli, &Staphylococcus aureus bacteria as well, provided cytotoxicity against tested cancer cell lines. These results can be explored to identify individual phyto-molecules from the extracts for anticancer &antimicrobial potentials to identify new phytomedicines.
If protective measures were widely adopted, they could significantly reduce women ’s chances of ever getting breast cancer.
[The Conversation Africa] Low-income communities in South Africa have the lowest incidence of breast cancer in the country. But they also have the worst health outcomes. Black South African women are the least likely segment of the population to have breast cancer but the most likely to die from it.
Night-shift work has been shown to be associated with breast cancer risk. Might it also play a role in prostate cancer development?American Journal of Epidemiology
SCIENTISTS say they can fight breast cancer by using ultrasound. Doctors would inject minute cell-like bubbles of drugs to travel through the lymphatic system, where the disease spreads.
I am a firm believer that medicine is best practiced as a team, with the one undergoing treatment at the center participating fully. It ’s a belief embedded in the multidisciplinary care model. I have been fortunate to have been exposed to multidisciplinary clinics in my fellowship at Memorial Sloan Kettering Cancer Center and have worked […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
AbstractPurpose of ReviewImmune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB, and anti-PD-L1 therapy is now approved in PD-L1+ metastatic TNBC, in combination with chemotherapy.Recent FindingsNearly 40% of PD-L1+ TNBC patients did not respond to this combination. Thus, additional biomarkers appear to be necessary to more precisely identify potential responders. A comprehensive analysis of the breas...
AbstractPurpose of ReviewThe purpose of this review is to explore the role of monocyte chemoattractant protein-1 (MCP-1 or CCL2) in the processes that underpin bone remodelling, particularly the action of osteoblasts and osteoclasts, and its role in the development and metastasis of cancers that target the bone.Recent FindingsMCP-1 is a key mediator of osteoclastogenesis, being the highest induced gene during intermittent treatment with parathyroid hormone (iPTH), but also regulates catabolic effects of continuous PTH on bone including monocyte and macrophage recruitment, osteoclast formation and bone resorption. In concer...
ConclusionsStrengths include an innovative model of referral and funding, through a life insurance provider, the involvement of a multidisciplinary collaborative team to design, develop and implement the pilot, and considerable consumer involvement.Implications for Cancer SurvivorsThe refined intervention will address a critical gap to improve reintegration into work and society, contributing to improved quality of life for cancer survivors in Australia. Models of referral through insurers to rehabilitation services could be adopted in other jurisdictions.